(PDF) Trivedi, M.H., McGrath, P.J., Fava, M., Parsey, R.V., Kurian, B.T., Phillips, M.L., Oquendo, M.A., Bruder, G., Pizzagalli, D., Toups, M., Cooper, C., Adams, P., Weyandt, S., Morris, D.W., Grannemann, B., Ogden, R.T., Buckner, R., McInnis, M., Kraemer, H.C., Petkova, E., Carmody, T.J., Weissman, M.M
Appendix 1 presents the PRISMA 12 flow chart of the study selection
Strategic shift: Novo Nordisk is actively winding down legacy and lower-margin insulin products, especially in developed markets, to prioritize next-generation basal insulins (Tresiba, Awiqli) and innovative GLP-1 therapies
Proper site selection forms the foundation of bruise prevention
The first was a multi-center study that used data from 33,021 participants and found that GLP-1/GIP agonist and SGLT2 inhibitor use were associated with comparable rates of new retinopathy development and worsening of existing nonproliferative retinopathy